campaign
Pfizer + Seagen — Building an Oncology Powerhouse
- Location
- New York + Global
- Dates
- December 14, 2023 – June 30, 2025
Pfizer's $43-billion acquisition of Seagen (closed December 2023) added leading antibody-drug conjugate (ADC) technology and cancer medicines including Padcev, Adcetris, and Tukysa, becoming one of pharma's largest oncology franchises. The integration is a central Pfizer strategy story covered by science journalists, biotech creators, and health-policy writers globally — including in India where cancer care remains a critical unmet need.
Credits (3)
